VivoSeq
Neurology

Neurofibromatosis 1

2

Pipeline Programs↗

3

Active Trials↗

2

Companies Involved↗

Neurofibromatosis 1 is an early-stage landscape with 2 programs across 2 companies. The most active players are Eli Lilly, AstraZeneca.

Intelligence

Pipeline Metrics

Competitive Density

22/100

Pipeline Velocity

0/100

Mech. Concentration

100/100

Completion Rate

0/100

Attrition Rate

25/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Eli Lilly logo

Eli Lilly

1 program

PreclinicalAstraZeneca logo

AstraZeneca

0 programs

Preclinical

Pipeline

Programs by Phase

Preclinical1

Abemaciclib

Eli Lilly

Phase 1
No programs
Phase 21

Aminolevulinic Acid

Biomed Industries, Inc.

Phase 3
No programs
Approved
No programs

Analysis

Trial Status

4

clinical trials

Recruiting3 · 75%
Terminated1 · 25%

Clinical Trials

Trial Activity

Development and Validation of Patient Reported Outcome (PRO) Measures for Individuals With Neurofibromatosis 1 (NF1) and Plexiform Neurofibromas (pNFs)
Recruiting·National Cancer Institute (NCI)·N/A·NCT02544022·476 enrolled
Topical Photodynamic Therapy (PDT) With Levulan® Kerastick® for Benign Dermal Neurofibromas Phase II
Terminated·—·Phase 2·NCT02728388·30 enrolled
A Phase 0/I/II Study of the Cyclin-Dependent Kinase(CDK)4/6 Inhibitor Abemaciclib for Neurofibromatosis Type 1 (NF1) Related Atypical Neurofibromas
Recruiting·National Cancer Institute (NCI)·Preclinical·NCT04750928·55 enrolled
Real-World Treatment Study of Koselugo (Selumetinib)
Recruiting·AstraZeneca logoAstraZeneca·N/A·NCT06360406·200 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)